IRIS Accounts Production v26.1.0.640 11811597 Board of Directors 1.7.24 30.6.25 30.6.25 8.6.26 true false true false false true false Auditors Opinion iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh 11811597 2024-06-30 11811597 2025-06-30 11811597 2024-07-01 2025-06-30 11811597 2023-06-30 11811597 2023-07-01 2024-06-30 11811597 2024-06-30 11811597 ns15:EnglandWales 2024-07-01 2025-06-30 11811597 ns14:PoundSterling 2024-07-01 2025-06-30 11811597 ns10:Director1 2024-07-01 2025-06-30 11811597 ns10:PrivateLimitedCompanyLtd 2024-07-01 2025-06-30 11811597 ns10:SmallEntities 2024-07-01 2025-06-30 11811597 ns10:Audited 2024-07-01 2025-06-30 11811597 ns10:SmallCompaniesRegimeForDirectorsReport 2024-07-01 2025-06-30 11811597 ns10:SmallCompaniesRegimeForAccounts 2024-07-01 2025-06-30 11811597 ns10:FullAccounts 2024-07-01 2025-06-30 11811597 ns10:Director2 2024-07-01 2025-06-30 11811597 ns10:Director3 2024-07-01 2025-06-30 11811597 ns10:Director4 2024-07-01 2025-06-30 11811597 ns10:CompanySecretary1 2024-07-01 2025-06-30 11811597 ns10:RegisteredOffice 2024-07-01 2025-06-30 11811597 ns5:CurrentFinancialInstruments 2025-06-30 11811597 ns5:CurrentFinancialInstruments 2024-06-30 11811597 ns5:ShareCapital 2025-06-30 11811597 ns5:ShareCapital 2024-06-30 11811597 ns5:RetainedEarningsAccumulatedLosses 2025-06-30 11811597 ns5:RetainedEarningsAccumulatedLosses 2024-06-30 11811597 ns5:PlantMachinery 2024-06-30 11811597 ns5:ComputerEquipment 2024-06-30 11811597 ns5:PlantMachinery 2025-06-30 11811597 ns5:ComputerEquipment 2025-06-30 11811597 ns5:PlantMachinery 2024-06-30 11811597 ns5:ComputerEquipment 2024-06-30 11811597 ns5:CostValuation 2024-06-30 11811597 ns5:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments 2025-06-30 11811597 ns5:CostValuation 2025-06-30 11811597 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2025-06-30 11811597 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2024-06-30 11811597 1 2024-07-01 2025-06-30

REGISTERED NUMBER: 11811597 (England and Wales)

| FINANCIAL STATEMENTS |

| FOR THE YEAR ENDED 30 JUNE 2025 |

| FOR |

| TIC CARDIO LIMITED |

| TIC CARDIO LIMITED (REGISTERED NUMBER: 11811597) |

CONTENTS OF THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2025

Page |

| Company Information | 1 |

| Balance Sheet | 2 |

| Notes to the Financial Statements | 3 |

| TIC CARDIO LIMITED |

COMPANY INFORMATION

FOR THE YEAR ENDED 30 JUNE 2025

| DIRECTORS: | A A Kleanthous

| P Georgiou

| C Kleanthous

| N A V Kleanthous

| SECRETARY: | P Georgiou

| REGISTERED OFFICE: | 1 Kings Avenue

| London

| N21 3NA

| REGISTERED NUMBER: | 11811597 (England and Wales)

| AUDITORS: | Xeinadin Audit Limited

| Level 5A

| Maple House

| 149 Tottenham Court Road

| London

| W1T 7NF

| TIC CARDIO LIMITED (REGISTERED NUMBER: 11811597) |

BALANCE SHEET

30 JUNE 2025

| 2025 | 2024 |

| Notes | £ | £ | £ | £ |

FIXED ASSETS

Tangible assets | 4 | - |  | - |  |

Investments | 5 | 60,010 |  | 240,000 |  |

60,010 |  | 240,000 |  |

CURRENT ASSETS

Debtors | 6 | 180,321 |  | 144,992 |  |

Cash at bank | 63,505 |  | 149,538 |  |

243,826 |  | 294,530 |  |

CREDITORS

Amounts falling due within one year | 7 | 105,497 |  | 242,463 |  |

NET CURRENT ASSETS | 138,329 |  | 52,067 |  |

TOTAL ASSETS LESS CURRENT LIABILITIES | 198,339 |  | 292,067 |  |

CAPITAL AND RESERVES

Called up share capital | 1,000 |  | 1,000 |  |

Retained earnings | 197,339 |  | 291,067 |  |

SHAREHOLDERS' FUNDS | 198,339 |  | 292,067 |  |

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 8 June 2026 and were signed on its behalf by:

A A Kleanthous - Director

| TIC CARDIO LIMITED (REGISTERED NUMBER: 11811597) |

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2025

1. | STATUTORY INFORMATION

| TIC Cardio Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

| The presentation currency of the financial statements is the Pound Sterling (£).

2. | ACCOUNTING POLICIES

| Basis of preparing the financial statements

| These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

| The director has a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. The director regards the foreseeable future as no less than twelve months following the publication of its annual financial statements. The director has considered the company's balance sheet position as at the year end, its working capital forecasts and projections, taking account of reasonably possible changes in trading performance and the current state of its operating market, and are satisfied that the company's financial position is improving and will enable the company to remain in operational existence. In addition, the director and shareholder has agreed to provide continuing financial support as and when required to enable the company to continue in operational existence. Consequently, the director considers it to be appropriate to prepare the financial statements on the going concern basis.

| Preparation of consolidated financial statements

| The financial statements contain information about TIC Cardio Limited as an individual company and do not contain consolidated financial information as the parent of a group. The company is exempt under Section 400 of the Companies Act 2006 from the requirements to prepare consolidated financial statements as it and its subsidiary undertaking are included by full consolidation in the consolidated financial statements of its parent, Double A Group Ltd, 1 Kings Avenue, London, United Kingdom, N21 3NA.

| Significant judgements and estimates

| In the application of the company's accounting policies, the director is required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

| The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period. or in the period of the revision and future periods where the revision affects both current and future periods.

| There are no significant judgements or estimates involved in the preparation of the financial statements.

| Revenue

| Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

| Revenue is in respect of medical services supplied by the Company and is recognised on completion of the service.

| Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable.

| Tangible fixed assets

| Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

| Plant and Machinery - 25% on Straight Line

| Computer Equipment - 100% on Straight Line

| Investments in subsidiaries

| Investments in subsidiary undertakings are recognised at cost.

| TIC CARDIO LIMITED (REGISTERED NUMBER: 11811597) |

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 30 JUNE 2025

2. | ACCOUNTING POLICIES - continued

| Financial instruments

| The Company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, and loans to and from related parties.

| Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

| Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours.

| Short term creditors are measured at the transaction price. Other financial liabilities are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

| Debt instruments that are payable or receivable within one year, typically trade debtors and creditors, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration expected to be paid or received.

| Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in profit or loss.

| For financial assets measured at amortised cost, the impairment loss is measured as the difference between an asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate.

| For financial assets measured at cost less impairment, the impairment loss is measured as the difference between an asset's carrying amount and best estimate of the recoverable amount, which is an approximation of the amount that the Company would receive for the asset if it were to be sold at the reporting date.

| Financial assets and liabilities are offset and the net amount reported in the statement of financial position when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

| Taxation

| Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

| Current or deferred taxation assets and liabilities are not discounted.

| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

| Deferred tax

| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

| Hire purchase and leasing commitments

| Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

3. | EMPLOYEES AND DIRECTORS

| The average number of employees during the year was 1 (2024 - 1 ) .

| TIC CARDIO LIMITED (REGISTERED NUMBER: 11811597) |

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 30 JUNE 2025

4. | TANGIBLE FIXED ASSETS

| Plant and |  | Computer |

| machinery |  | equipment |  | Totals

£ | £ | £ |

| COST

| At 1 July 2024

| and 30 June 2025 | 15,646 |  | 600 |  | 16,246 |  |

| DEPRECIATION

| At 1 July 2024

| and 30 June 2025 | 15,646 |  | 600 |  | 16,246 |  |

| NET BOOK VALUE

| At 30 June 2025 | - |  | - |  | - |  |

| At 30 June 2024 | - |  | - |  | - |  |

5. | FIXED ASSET INVESTMENTS

| Shares in

| group

| undertakings

£ |

| COST

| At 1 July 2024 | 240,000 |  |

| Impairments | (179,990 | ) |

| At 30 June 2025 | 60,010 |  |

| NET BOOK VALUE

| At 30 June 2025 | 60,010 |  |

| At 30 June 2024 | 240,000 |  |

6. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

£ | £ |

| Trade debtors | 26,798 |  | 144,000 |  |

| Amounts owed by group undertakings | 146,833 |  | - |  |

| Other debtors | 6,690 |  | 992 |  |

180,321 |  | 144,992 |  |

7. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

£ | £ |

| Trade creditors | 729 |  | 2,000 |  |

| Amounts owed to group undertakings | 60,010 |  | 182,810 |  |

| Taxation and social security | 11,868 |  | 37,426 |  |

| Other creditors | 32,890 |  | 20,227 |  |

105,497 |  | 242,463 |  |

8. | DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

| The Report of the Auditors was unqualified.

| Anthony Cowan BSc FCA (Senior Statutory Auditor)

| for and on behalf of Xeinadin Audit Limited

| TIC CARDIO LIMITED (REGISTERED NUMBER: 11811597) |

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 30 JUNE 2025

9. | RELATED PARTY DISCLOSURES

| The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

| Amounts owed to and from group and related undertakings are non-interest bearing and repayable on demand.

10. | POST BALANCE SHEET EVENTS

| No significant events have occurred between the reporting date, 30 June 2025, and the date the financial statements were authorized for issue that would require adjustment to or disclosure in the financial statements.

11. | ULTIMATE CONTROLLING PARTY

| The ultimate controlling party is A A Kleanthous.

| The Company is 100% owned subsidiary of TIC Health Limited which is 100% owned subsidiary of TIC Medical Group Holdings Limited, a Company incorporated in the England and Wales, whose registered office is 1 Kings Avenue, London, United Kingdom, N21 3NA.

| The ultimate parent undertaking in which the Company's results are consolidated is Double A Group Ltd a private limited company registered in England and Wales. Copies of the consolidated Financial Statements of Double A Group Ltd can be obtained from the registered office at 1 Kings Avenue, London, United Kingdom, N21 3NA.